A, amphetamine; BG, benzedrine group; PCAG, pentobarbital, chlorpromazine, alcohol group. Mean values are not included for a particular measure if the repeated-measure analysis of variance failed to show a significant effect of the dose. Bold values: significant differences (P < 0.05) from placebo according to post-hoc tests.
Progressive-ratio schedules are useful for studying the reinforcing effects of drugs. Earlier human laboratory studies showed that d-amphetamine significantly increased break points relative to placebo. However, the magnitude of the increase was modest, which may be attributable to rather high levels of placebo responding. We used novel response requirements in a modified progressive-ratio procedure and hypothesized that the altered range of response requirements would decrease responding for placebo and increase responding for d-amphetamine. Eight participants completed the study. The participants first sampled oral doses of d-amphetamine (0, 8, 16, and 24 mg) . In subsequent sessions, the participants were offered the opportunity to work for the sampled dose on a modified progressive-ratio procedure with response requirements ranging from 400 to 1800 mouse clicks. A battery of participant-rated drug-effect questionnaires, a performance measure, and cardiovascular measures were included to more fully characterize the effects of d-amphetamine. Placebo maintained low levels of responding. The intermediate dose of d-amphetamine increased responding significantly above placebo levels. d-Amphetamine produced prototypical subject-rated effects that were an orderly function of dose. These data suggest that the modified response requirements resulted in lower levels of placebo taking and a larger separation between the number of placebo and d-amphetamine capsules earned. Behavioural Pharmacology 21:745-753 c 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Introduction
The reinforcing effects of drugs are central to their abuse (Foltin and Fischman, 1991) . Progressive-ratio schedules have been useful in assessing the reinforcing effects of abused drugs (Richardson and Roberts, 1996; Stoops, 2008) . Under a progressive-ratio schedule, the response requirement (i.e. ratio) for obtaining each subsequent reinforcer is progressively increased, until the participant ceases to respond. The final ratio completed to obtain a reinforcer is termed as the break point (often the dependent measure), which presumably reflects the maximum effort that a participant will expend to receive the reinforcer (Richardson and Roberts, 1996) . Commonly abused stimulants such as cocaine, d-amphetamine, methamphetamine, and methylphenidate dose-dependently increased break points on progressive-ratio schedules in animals (Griffiths et al., 1975 (Griffiths et al., , 1979 Poncelet et al., 1983; Ranaldi and Wise 2000; Woolverton and Wang, 2004; Brebner et al., 2005) . Progressive-ratio schedules are widely used in preclinical studies because they are thought to measure the reward strength or reinforcing efficacy of a drug dose (for reviews see Richardson and Roberts, 1996; Stafford et al., 1998) .
Progressive-ratio schedules have also been adapted for use in humans. Laboratory studies conducted in humans have shown that progressive-ratio schedules are sensitive to the reinforcing effects of abused stimulants. Methylphenidate, for example, maintained respond under a progressive-ratio schedule and increased break points (i.e. the last ratio completed) significantly above placebo levels in humans (Stoops et al., 2004) . Several earlier studies have assessed the reinforcing effects of oral damphetamine using a progressive-ratio schedule modified for use in humans (Rush et al., 2001; Stoops et al., 2004 Stoops et al., , 2007a Stoops et al., , 2007b . In the first two of our studies, the response requirement under the progressive-ratio schedule ranged from 50 to 6400 clicks (i.e. 50, 100, 200, 400, 800, 1600, 3200 , and 6400 clicks) on a computer mouse (Rush et al., 2001; Stoops et al., 2004) , whereas for the other studies the response ratios ranged from 25 to 3200 clicks (i.e. 25, 50, 100, 200, 400, 800, 1600 , and 3200 clicks) (Stoops et al., 2007a (Stoops et al., , 2007b . In each of these studies at least one dose of d-amphetamine increased the break points significantly above placebo levels. However, the magnitude of the increase was modest. The small magnitude of the effects of d-amphetamine observed in our earlier studies may make it difficult to manipulate the reinforcing effects of d-amphetamine pharmacologically.
In addition, it is worth noting that response to placebo was relatively high in our earlier studies that used a progressive-ratio procedure (Rush et al., 2001; Stoops et al., 2004 Stoops et al., , 2007a Stoops et al., , 2007b . On average, participants completed 3.3 out of the 8 response ratios to receive placebo. Animal studies have shown that the ability to resolve the behavioral effects of d-amphetamine and related stimulants is blunted under conditions with high levels of baseline operant response (Smith, 1964; McMillan, 1969) . Therefore, the relatively low, albeit statistically significant, self-administration of d-amphetamine observed in our earlier studies could be, in part, because of high levels of response to placebo.
The present experiment was designed to refine the progressive-ratio schedule for assessing the reinforcing effects of d-amphetamine. In this experiment, we used novel response requirements (400-1800 clicks) under the modified progressive-ratio schedule. We hypothesized that the altered range of response requirements (i.e. higher 'minimal' response requirements and lower 'maximal' response requirements) would decrease response to placebo and increase response to amphetamine, which could enhance our ability to measure the reinforcing effects of d-amphetamine. Refining laboratory procedures, such as progressive-ratio schedules, is important if these procedures are to be used for assessing the initial efficacy of potential pharmacotherapies for amphetamine dependence (Haney and Spealman, 2008; Stoops, 2008) .
Methods

Participants
Nine healthy adult humans were recruited from the local community, through newspaper advertisements, flyers, and word of mouth, to participate in this experiment. One of these participants was discharged from the study because his blood pressure exceeded our predetermined safety criteria (i.e. systolic blood pressure was greater than 165 mmHg) during the sampling session for the high d-amphetamine dose. Data from this participant were not included in the analyses. Thus, eight participants (two men, six women; seven white, one black) completed the experiment. The participants were paid $40 at the end of each session for their participation, and received a $400 completion bonus (i.e. $40 for each completed session) at the end of the entire experiment. Thus, the participants received a total of $800 for completing the experiment.
The participants ranged in age from 19 to 25 years (mean = 21), in education from 12 to 16 years (mean = 15), and in weight from 53 to 88 kg (mean = 66). All the participants reported recreational stimulant use within the past year, but they did not meet the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for stimulant or other drug use disorders. Five participants reported amphetamine use in the year before enrollment; four used Adderall and one used ecstasy. One participant reported cocaine use in the year before enrollment. Two participants reported using amphetamine (Adderall) and cocaine in the year before enroll-ment. All the participants reported lifetime use of marijuana, reporting having used marijuana for 4.6 years on average before screening for the study. Five, three, and two participants reported lifetime use of opioids, benzodiazepines, and hallucinogens, respectively.
Before enrollment, all potential participants completed a standard comprehensive medical, physical, and psychological screen. Routine clinical laboratory blood and urine chemistry tests and an electrocardiogram were conducted on all potential participants. Potential participants with histories of serious physical disease, current physical disease (e.g. impaired cardiovascular functioning, chronic obstructive pulmonary disease, etc.), seizure, head trauma or central nervous system tumors, or current or past histories of serious psychiatric disorder (i.e. Axis I, DSM-IV), including attention deficit hyperactivity disorder and substance abuse or dependence disorders (except nicotine), were excluded from participation. All the participants were in good health with no contraindications to stimulant medications. The criteria for female participants were to report using an effective form of birth control and not be pregnant. Hence, all female participants were also screened for pregnancy (urine HCG; Mainline Technology, Ann Arbor, Michigan, USA) before each session to ensure that they did not continue in the study if pregnant. None of the female participants tested positive for pregnancy throughout the experimental protocol.
The Institutional Review Board of the University of Kentucky Chandler Medical Center approved this study and the informed consent document. The participants signed the informed consent after passing appropriate sobriety tests and before enrolling in the study.
General procedures
The participants enrolled as outpatients at the Laboratory of Human Behavioral Pharmacology at the University of Kentucky Chandler Medical Center. They completed a total of 10 sessions (two practice sessions and eight experimental sessions).
The participants were informed that during their participation they would receive various drugs and that these could include placebo and d-amphetamine. Other than this general information, the participants were blind to the type of drug administered. They were told that the purpose of the study was to see how different drugs affect mood and behavior, and whether they would be willing to work to receive the drugs. The participants were given no instruction on what they were 'supposed' to do or what outcomes might be expected. They were asked to abstain from all drug (illicit and licit) use for the duration of the experiment, with the exception of nonsteroidal antiinflammatory analgesics and nicotine. In addition, the participants were also asked not to ingest food or caffeine for 4 h before each experimental session, and alcohol for 12 h before and after each experimental session.
Experimental sessions were generally conducted daily, Monday through Friday. The time of day at which each session began was held constant for individual participants. On experimental session days, the participants followed a daily routine. On each experimental session day the participants were first provided a light breakfast. Then the participants were provided with an expired air sample, which was assayed for the presence of alcohol using an Alco-Sensor breathalyzer (Intoximeters, St Louis, Missouri, USA), and later also underwent a field sobriety test. The participants had to provide a breath sample negative for alcohol and pass the field sobriety test to continue with the scheduled experimental session. At the beginning of each session, the participants provided a urine sample that was screened for the presence of amphetamines, barbiturates, benzodiazepines, cocaine, opioids, and tetrahydrocannabinol (THC). If a urine sample was positive for any drug, other than THC or compounds administered experimentally, the session was canceled until the participant provided a drug-free urine sample. No participants tested positive for the presence of drugs other than those administered experimentally or THC throughout the experimental protocol. The participants who reported the use of tobacco were permitted to smoke one tobacco cigarette midway through the experimental session. They were not able to smoke again until the experimental testing was completed.
Experimental design Practice sessions
Before beginning the experiment, the participants completed two 'practice' sessions. These practice sessions were used to familiarize the participants with the modified progressive-ratio procedure, subject-rated drugeffect questionnaires, performance measure, and daily laboratory routine, all of which are described below. No medications were administered on these days.
Experimental sessions
The participants completed the presession task between 08:30 and 08:45 h, the modified progressive-ratio procedure (only on self-administration sessions) between 08:50 and 10:00 h, ingested drug at approximately 10:00 h, and then completed the subject-rated drug-effect questionnaires and performance task at hourly intervals for 5 h. A minimum of 24 h generally separated all drug administrations. One to three participants were enrolled in this experiment at a time. The participants were instructed not to discuss their drug effects with each other during the sampling or self-administration sessions, or outside the laboratory.
Testing of each of the drug conditions described below consisted of two separate sessions: (i) a sampling session and (ii) a self-administration session, both of which were conducted on separate days. Sampling sessions were immediately followed by self-administration sessions on the next experimental session day.
Sampling sessions: Sampling sessions were conducted to acquaint the participants with the effects of each drug dose. After the predrug questionnaires were completed and cardiovascular measures recorded, the participants were instructed to pay attention to and make notes about the effects of the drug because they would be offered the opportunity to work to receive that drug again in a future session. The participants then ingested eight identical capsules, and completed the subject-rated drug-effect questionnaires, cardiovascular measures, and performance task at hourly intervals for 5 h. In addition to the standardized subject-rated drug-effect questionnaires, each participant was given a notebook in which they recorded individual comments concerning the effects of the drug dose.
Self-administration sessions: Self-administration sessions were generally conducted 24 h after the sampling sessions. Self-administration sessions differed from sampling sessions only in that the participants had to earn capsules by responding on a modified progressive-ratio procedure. After the predrug questionnaires were completed and cardiovascular measures recorded, the participants were given a sheet of paper that contained instructions regarding the self-administration session.
Modified progressive-ratio procedure During each self-administration session, the participants were given eight opportunities to respond on a standard Apple mouse (Apple, Cupertino, California, USA) to earn all, or some, of the capsules that were administered during the preceding sampling session (i.e. the earlier experimental session day). Before each of the eight opportunities to earn a capsule, the participants were asked whether they wanted to work for one of yesterday's capsules. If the participants wanted to work, they responded by clicking on a button on the computer screen, labeled 'Click here for 1 capsule'. The participants were required to click the computer mouse for a predetermined number of times to earn a capsule. To earn the first capsule, the participants had to click the mouse 400 times. The number of clicks required to earn each additional capsule was increased by 200 clicks (i.e. 600, 800, 1000, 1200, 1400, 1600, and 1800 clicks). To receive all the eight capsules, the participants had to click the mouse a total of 8800 times. While completing each component of the progressive-ratio schedule, the participants were also able to terminate the task by clicking on a button labeled 'stop'. The dependent measure on this task was the number of capsules earned.
The participants ingested all of the capsules they earned immediately after completing the modified progressiveratio schedule. Each capsule contained 12.5% of the total dose of the test drug administered during the preceding d-amphetamine effects in progressive-ratio schedule Sevak et al. 747 sampling session. Thus, if a participant responded for all eight capsules during a self-administration session, he/she earned the total dose received during the preceding sampling session. After ingesting any capsules earned on the modified progressive-ratio procedure, the participants completed the subject-rated drug-effect questionnaires and performance task at hourly intervals for 5 h. If a participant did not respond for any capsules, he/she still completed the subject-rated drug-effect questionnaires and performance task at hourly intervals for 5 h. The participants began completing the subject-rated drugeffect questionnaires and performance tasks at hourly intervals for 5 h at a fixed time (i.e. approximately 11:00 a.m.). This ensured that the participants did not refuse to respond in an attempt to shorten the self-administration sessions.
Self-report questionnaires, performance task, cardiovascular measures Three self-reported drug-effect questionnaires and a performance task were administered on an Apple MacIntosh computer and were completed in a fixed order. These questionnaires were completed approximately 30 min before drug administration, and at hourly intervals for 5 h after drug administration.
Addiction Research Center Inventory
The short form of the Addiction Research Center Inventory consisted of 49 true/false questions and five major subscales: the morphine-benzedrine group (a measure of euphoria), the pentobarbital, chlorpromazine, alcohol group (PCAG; a measure of sedation), the lysergic acid diethylamide (a measure of dysphoria), and the benzedrine group and amphetamine scales (BG and A, respectively; Stimulant-Sensitive Scales) (Jasinski, 1977; Martin et al., 1971) .
Adjective Rating Scale
The Adjective Rating Scale (ARS) consisted of 32 items and two subscales: Sedative and Stimulant. These subscales are sensitive to the acute effects of orally administered sedative and stimulant drugs (Oliveto et al., 1992) . The participants rated each item using the computer mouse to point to and select among one of five response options: Not at All, A Little Bit, Moderately, Quite a Bit, and Extremely (scored numerically from 0 to 4, respectively).
Drug-Effect questionnaire
The questionnaire consisted of 20 items, which were presented on the computer screen one at a time (see Rush et al., 2003 for the items rated). The participants rated each item on a 0 to 100 scale anchored with 'not at all' on the leftmost extreme and 'extremely' on the rightmost extreme.
Digit-symbol substitution test
A computerized version of the digit-symbol substitution test (DSST), which has been described earlier, was used in this experiment (McLeod et al., 1982) . This measure is sensitive to the effects of orally administered sedative and stimulant drugs (Rush et al., 2003) . Briefly, the participants used a numeric keypad to enter a geometric pattern associated with one of the nine digits displayed on a video screen. The participants had 90 s to enter as many geometric patterns as possible. The dependent measure was the number of patterns completed (i.e. trials completed) and the number of patterns entered correctly (i.e. correct trials).
Heart rate and blood pressure
Heart rate and blood pressure were recorded, using an automated blood pressure monitor (Spot Vital Signs LXi, Welch Allyn, Skaneateles Falls, New York, USA), for approximately 30 min before drug administration and at hourly intervals for 5 h afterward, and immediately before the participants completed the self-reported drug-effect questionnaires and performance task.
Drug administration
All drug conditions were administered in a double-blind manner. During each sampling session, the participants orally ingested eight capsules with approximately 150 ml of water. During self-administration sessions, the participants orally ingested the number of capsules earned during the modified progressive-ratio procedure with approximately 150 ml of water. The doses were prepared using commercially available d-amphetamine (Barr Labs, Pomona, New York, USA). Each capsule contained 0 mg d-amphetamine (for the placebo dose), 1 mg d-amphetamine (for the 8 mg total dose), 2 mg d-amphetamine (for the 16 mg total dose), or 3 mg d-amphetamine (for the 24 mg total dose). Cornstarch was used to fill the remainder of all the capsules. Placebo capsules contained only cornstarch. The order of drug and dose administration was random, except that, for safety purposes, the participants never received the highest dose (24 mg) in the first experimental session. Drug administration procedures were designed to ensure that participants swallowed the capsules and did not open them in their mouths and taste the contents (Abreu and Griffiths, 1996) .
Data analysis
Statistical analyses of group data were conducted to examine drug effects on the modified progressive-ratio procedure, subject-rated drug-effect questionnaires, performance task, and cardiovascular measures. For all statistical analyses, effects were considered significant for a P value less than or equal to 0.05.
The number of capsules earned on the modified progressive-ratio procedure was analyzed using a repeatedmeasures analysis of variance with dose (0, 8, 16, and 24 mg) as the factor. If a significant effect of dose was detected in the analysis of variance, post-hoc tests (Fisher's least significant difference) were conducted to compare each of the three doses of d-amphetamine with placebo.
Data from the sampling sessions were analyzed to assess the effects of amphetamine on the subject-rated drugeffect questionnaires, performance task, and cardiovascular measures. Peak effect (i.e. the maximum value from 1 to 5 h after the drug administration) was calculated for each participant. Area under the time-action curve (AUC) was calculated for each participant using the trapezoidal method (Pollard, 1979) . Peak effect and AUC data were analyzed in the same manner as data from the modified progressive-ratio procedure. The result of the analyses of the peak effect and AUC data were similar; for the sake of brevity, only AUC data are presented. As the participants ingested varying amounts of drug during the self-administration sessions, subject-rated drug -effect questionnaire, performance, and cardiovascular data from the self-administration sessions were not analyzed statistically.
Results
Modified progressive-ratio performance
A main effect of the dose was found on the number of capsules earned by the modified-progressive-ratio procedure [F(3,21) = 3.4 P < 0.05]. Figure 1 shows that the intermediate dose of amphetamine (16 mg) increased response significantly to above placebo levels.
Subject-rated drug effects, performance, and cardiovascular measures Addiction Research Center Inventory
A significant effect of the dose was found on the A, BG, and PCAG Scales of the ARCI [F(3,21) = 5.1, 3.7, and 5.2, respectively; P < 0.05]. The high dose of d-amphetamine, 24 mg, increased responses on the A and BG Scales significantly to above placebo levels (Table 1) . Each dose of d-amphetamine decreased responses on the PCAG Scale significantly below levels observed with placebo (Table 1) . d-Amphetamine did not affect responses in the morphine-benzedrine group or lysergic acid diethylamide Scale to a statistically significant degree (data not shown).
Adjective Rating Scale
A significant effect of the dose was found on the Stimulant Scale of the ARS [F(3,21) = 9.4 P < 0.005]. Each dose of d-amphetamine increased responses on this scale significantly to levels above that observed with placebo (Table 1) . d-Amphetamine did not affect responses on the Sedative Scale of the ARS to a statistically significant degree (data not shown). Figure 1 shows the effects of d-amphetamine on six representative items: Any Effect, Active-Alert-Energetic, Good Effects, Like Drug, Willing to Pay For, and Stimulated. Each dose of d-amphetamine increased subject ratings of Any Effect significantly above levels observed with placebo, whereas the intermediate and high dose of increased subject ratings of Active-Alert-Energetic, Good Effects, Like Drug, Willing to Pay For, and Stimulated.
Digit-symbol substitution test
A significant effect of dose was found on number of trials corrected on the DSST [F(3,21) = 3.5 P < 0.05]. The intermediate and high doses of d-amphetamine increased the number of trials completed correctly to significantly above placebo levels (Table 1) . d-Amphetamine did not affect the total number of trials completed to a statistically significant degree (data not shown).
Heart rate and blood pressure d-Amphetamine increased systolic and diastolic blood pressure as an orderly function of the dose [F(3,21) = 14.7 and 16.4, respectively; P < 0.001]. Each dose of d-amphetamine increased the systolic and diastolic blood pressure significantly above levels observed with placebo (Table 1) . d-Amphetamine did not increase heart rate to a statistically significant degree (data not shown).
Discussion
This study examined the reinforcing effects of damphetamine using novel response ratios in a modified progressive-ratio procedure. The results indicate that placebo maintained low levels of responding and the intermediate dose of d-amphetamine increased responding significantly above placebo levels. Moreover, d-amphetamine produced prototypical subject-rated drug effects that were orderly functions of dose. These data suggest that the modified response requirements resulted in lower levels of placebo taking and a larger separation between the number of placebo and d-amphetamine capsules earned.
Human laboratory studies have shown that progressive-ratio schedules are sensitive to the reinforcing effects of a number of drugs, including heroin, marijuana, pentobarbital, caffeine, and cocaine (McLeod and Griffiths, 1983;  d-amphetamine effects in progressive-ratio schedule Sevak et al. 749 Griffith et al., 1989; Comer et al., 1997; Haney et al., 1997 Haney et al., , 1998 . The current results are concordant with the earlier findings from our laboratory showing that d-amphetamine functions as a reinforcer under a progressive-ratio schedule (Rush et al., 2001; Stoops et al., 2004 Stoops et al., , 2007a Stoops et al., , 2007b . These earlier studies used response requirements ranging from either 50 to 6400 or 25 to 3200 mouse clicks under the progressive-ratio procedure and at least one dose of damphetamine increased break points significantly above placebo levels. However, the response to placebo was relatively high in these earlier studies, that is, on average, the participants completed 3.3 out of the eight response ratios to earn the placebo capsules. The participants completed, on average, 4.5, 5.2, and 3.1 out of the eight response ratios to earn small (8 or 10 mg), medium (16 or 20 mg), and large (24 mg) doses of d-amphetamine, respectively (Rush et al., 2001; Stoops et al., 2004 Stoops et al., , 2007a Stoops et al., , 2007b . Thus, the high response to the placebo resulted in modest separations between the number of placebo and damphetamine capsules earned. In the present experiment, we used novel response requirements (400-1800 clicks) under the modified progressive-ratio schedule. We observed decreased response to placebo relative to our earlier studies, likely because of the higher initial response requirement. The decreased placebo response resulted in a larger separation between the number of placebo and d-amphetamine capsules earned, which may enhance our ability to detect a shift in the d-amphetamine Dose-response functions for number of capsules earned by the progressive-ratio procedure, along with subjective ratings of Any Effect, Active- dose-response curve. Thus, this procedure could be useful for assessing pharmacological modification of the reinforcing effects of amphetamines.
The results of this experiment are also concordant with the findings from animal studies that showed that damphetamine and related stimulants function as reinforcers under progressive-ratio schedules (Griffiths et al., 1975 (Griffiths et al., , 1979 Poncelet et al., 1983; Ranaldi and Wise 2000; Woolverton and Wang, 2004; Brebner et al., 2005) . Several studies conducted with animals have shown that stimulants produce inverted-U-shaped dose-response curves under progressive-ratio schedules (e.g. Griffiths et al., 1979; Martelle et al., 2008) . However, in humans ethical and safety concerns limit the feasibility of studying large doses of abused drugs, and therefore reduce the possibility of obtaining inverted-U-shaped dose-response curves (see Fischman and Johanson, 1998) . Worth noting is that an inverted-U-shaped dose-response curve of d-amphetamine was obtained using the progressive-ratio schedule in this and an earlier human laboratory study (Stoops et al., 2004) . Some theorists have suggested that ascending and descending limbs of the inverted-U-shaped curves involve distinct receptor mechanisms (Kenakin 1987; Rowlett 2000; Collins et al., 2005) . Therefore, the current procedure could be a useful noninvasive tool for studying mechanisms of effects of potential pharmacotherapies that shift the ascending and/or descending limbs of the d-amphetamine dose-response curve in humans.
Subject-rated effects are the most widely used behavioral measures in human laboratory experiments for assessing the abuse related effects of stimulants. In this study, damphetamine produced an array of positive subject-rated effects across the range of doses tested (e.g. increased ratings of Good Effects, Like Drug). The dose-dependent enhancement observed in the subject-rated effects of d-amphetamine is consistent with earlier reports (Martin et al., 1971; Rush et al., 1998; Sevak et al., 2009) . The potency of d-amphetamine for enhancing the positive subject-rated effects was also similar to that reported in earlier studies (Stoops et al., 2004 (Stoops et al., , 2007a . Moreover, concordant with the findings from earlier studies, d-amphetamine enhanced the number of trials completed correctly on the DSST, indicating improvements in motor performance (Rush et al., 2003; Stoops et al., 2004) . Thus, in agreement with the published findings, the results of this study indicate that damphetamine increases positive subject-rated effects as an orderly function of dose.
The present results indicate that the reinforcing and subject-rated effects of drugs are not isomorphic. The intermediate dose of d-amphetamine increased the number of capsules earned above placebo levels, whereas in general, the two higher doses of d-amphetamine produced prototypical stimulant-like subject-rated effects. These findings are consistent with earlier research showing that positive subject-rated effects and reinforcing effects are dissociable Uhlenhuth, 1980, 1981; Lamb et al., 1991; Haney et al., 1999) . Thus, the present data suggest that positive subject-rated effects of d-amphetamine do not entirely account for the drug-taking behavior in the laboratory and that these two behavioral measures do not assess the same mechanism that is related to the abuse of d-amphetamine.
Although this study made an advance in attempts to separate placebo and stimulant drug self-administration in the progressive-ratio paradigm in humans, only one dose of d-amphetamine increased the number of capsules earned significantly above placebo levels. Notably, this result indicated an improvement from the earlier findings (in our earlier studies the average separation between the placebo and d-amphetamine (16 mg) self-administration was 1.8 response ratios, whereas in this study that was 3.4 response ratios). However, future modifications and refinements (e.g. changes in response requirements, dose selections) are needed to further enhance the sensitivity of the procedure. Worth noting is the inherent difficulty in separating placebo and stimulant drug self-administration under progressive-ratio procedures, or other models of drug-taking in humans, without the extensive training that can be imposed in nonhuman animals. Notably, human laboratory studies involving extensive training before test sessions (e.g. drug-discrimination) show a large separation between placebo and stimulant drug effects (Jones et al., 2001) , and also improve outcomes of subject-rated behavioral measures (Rush et al., 1998 (Rush et al., , 2003 Sevak et al., 2009 ). Future progressive-ratio studies incorporating this methodological improvement (i.e. extensive training before test sessions) may enhance the sensitivity of the procedure to better separate the placebo and stimulant drug effects. Nonetheless, progressive-ratio procedures can still be useful for assessing pharmacological modifications of behavioral effects of stimulants with improved methodology and enhanced sensitivity that can detect a large magnitude of reinforcing effects (Stoops, 2008) . To that end, we believe this study provides an important contribution to a laboratory model of drug taking, which should be further refined to obtain more sensitive human laboratory procedures for evaluating potential medications for the management of stimulant dependence.
In summary, these data suggest that the modified response requirements under the progressive-ratio procedure resulted in lower levels of placebo taking and a larger separation between the number of placebo and d-amphetamine capsules earned, which may enhance our ability to detect a shift in the d-amphetamine doseresponse curve. Thus, this procedure could be well suited for assessing pharmacological modification of the reinforcing effects of amphetamines. Reinforcing effects are central to the abuse of amphetamines and related stimulants; hence, a drug that modifies the reinforcing effects of amphetamines can be expected to be effective for the management of amphetamine dependence (Foltin and Fischman, 1991) . The findings from this study may, therefore, facilitate the human laboratory evalua-tions of potential medications for managing amphetamine dependence.
